ICare-FASTER (Improving Care by Faster Risk Stratification Through Use of High-Sensitivity Point-of-Care Troponin in Patients Presenting With Possible Acute Coronary Syndrome in the Emergency Department): A Stepped-Wedge Cluster-Randomized Trial.
Implementation of whole-blood hs-cTnI testing at the point of care into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing.
Abstract
Background
Point-of-care high-sensitivity cTn (cardiac troponin; hs-cTn) testing has the potential to expedite decision-making and reduce emergency department (ED) length of stay for patients presenting with possible myocardial infarction by ensuring that results are consistently available when sought by clinicians. We assessed the real-life effectiveness and safety of implementing point-of-care hs-cTn testing in the ED.
Methods
We conducted a pragmatic, stepped-wedge cluster-randomized trial. The control arm was usual care with an accelerated diagnostic pathway using a single-sample rule-out step with a central laboratory hs-cTn assay. The intervention arm used the same pathway with a point-of-care hs-cTnI assay. The primary effectiveness outcome was ED length of stay assessed using a generalized linear mixed model. The safety outcome was myocardial infarction or cardiac death within 30 days.
Results
Six sites participated, with 59 980 ED presentations (44 747 individuals; mean 61±19 years of age; 49.5% female) from February 2023 through January 2025; 31 392 presentations were during the intervention arm. After adjustment for covariates associated with length of stay, the intervention reduced length of stay by 13% (95% CI, 9%-16%; P<0.001), corresponding to a reduction of 47 minutes (95% CI, 33-61 minutes) from a mean length of stay in the control arm of 376 minutes. The 30-day myocardial infarction or cardiac death rate was similar in the control and intervention arms (0.39% and 0.39%, respectively; P=0.54).
Conclusions
Implementation of whole-blood hs-cTnI testing at the point of care into an accelerated diagnostic pathway was safe and reduced length of stay in the ED compared with laboratory testing.
REGISTRATION
URL: https://www.anzctr.org.au; Unique identifier: ACTRN12619001189112.
The i-STAT hs-cTnI assay demonstrated high agreement with the Abbott Alinity platform for troponin-based risk classification and correctly identified all myocardial infarction cases, suggesting that the i-STAT assay may be safely used for early risk stratification of ED patients, particularly for identifying low-risk p...
Merih T. Tesfazghi, Elif Yucebay, I. Espinosa et al.· Clinical Chemistry· 0 citations
High-sensitivity troponin testing at the point-of-care (POC) level may enable faster and more accurate assessment of chest pain in low-resource, out-of-hospital settings. The ongoing prospective OUT-POC study (One-hoUr Troponin using a high-sensitivity Point-Of-Care assay in emergency primary care), initiated in...
T. Johannessen, D. Atar, S. Halvorsen et al.· European Heart Journal· 0 citations
BackgroundPoint-of-care (POC) high-sensitivity cardiac troponin I (hs-cTnI) testing can reduce diagnostic turnaround in the emergency department (ED), but real-world operational data remain mixed.MethodsObservational before-after service evaluation at a high-volume UK tertiary ED (Queen Elizabeth University Hospital, G...
Faheem Ahmad, U. Razzaq, Vaishnavi Muthukrishnan et al.· Scottish Medical Journal· 0 citations
High-sensitivity cardiac troponin (hs-cTn) assays have significantly enhanced the diagnosis in patients suspected of acute coronary syndrome (ACS). New hs-cTn point-of-care (POC) devices (turnaround time <20 min) may significantly reduce time to diagnosis. We evaluated the diagnostic accuracy of four currently commerci...
Lara E. van Daalen, Bart L. F. Schueler, P. Collinson et al.· European journal of emergenc...· 0 citations
Point-of-care (POC) high-sensitivity cardiac troponin (hs-cTn) assays provide rapid turnaround times and are increasingly considered for use within guideline recommended 0/1-hour accelerated diagnostic protocols (ADPs). However, higher per-test costs raise concerns regarding overall economic impact. Randomised ev...
I. V. L. Thulin, S. M. F. Jordalen, J. J. Gangstoe et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.